Results of preoperative antitumor therapy in combination with bevacizumab and KRAS status during liver resections for colorectal cancer metastases


Cite item

Full Text

Abstract

Whether it is expedient and safe to add bevacizumab to preoperative treatment regimens for colorectal cancer liver metastases has been remained unclear over many years in spite of the duration of its use in this category of patients. In our trial, incorporation of bevacizumab into preoperative therapy was also accompanied by an increase in disease control and a significant reduction in the risk of disease progression during chemotherapy versus other treatment regimens. Comparison with a subgroup of patients treated with oxaliplatin-based regimens without bevacizumab showed that the significance of their difference disappeared; however, a clear trend persisted in favor of bevacizumab addition. KRAS is the only molecular marker used to select patients for therapy with monoclonal antibodies. Our findings also suggest that particular emphasis should be laid on the KRAS status in patients receiving bevacizumab therapy. Random estimation of the KRAS status in the patients who had undergone successful preoperative therapy and liver resection displayed a clear tendency towards the prevalence of the wide-type gene as compared with population-wide data.

About the authors

M I Sekacheva

ФГБУ Российский научный центр хирургии им. акад. Б.В.Петровского РАМН, Москва

Email: sekach_rab@mail.ru
канд. мед. наук, врач-онколог, ученый секретарь

N N Bagmet

ФГБУ Российский научный центр хирургии им. акад. Б.В.Петровского РАМН, Москва

канд. мед. наук, вед. науч. сотр. отд-ния хирургии печени желчных путей и поджелудочной железы

L O Polishchuk

ФГБУ Российский научный центр хирургии им. акад. Б.В.Петровского РАМН, Москва

канд. мед. наук, ст. науч. сотр.

O V Glazova

ФГБУ Российский научный центр хирургии им. акад. Б.В.Петровского РАМН, Москва

мл. науч. сотр. лаб. медицинской генетики

E V Zaklyazminskaya

ФГБУ Российский научный центр хирургии им. акад. Б.В.Петровского РАМН, Москва

д-р мед наук, зав. лаб. медицинской генетики

O G Skripenko

ФГБУ Российский научный центр хирургии им. акад. Б.В.Петровского РАМН, Москва

д-р мед наук, проф., зам. дир. по научной работе; зав. отд-нием хирургии печени желчных путей и поджелудочной железы

References

  1. Ferlay J, Shin H.R, Bray F et al. GLOBOCAN 2008, Version 1,2. Cancer Incidence and Mortality Worldwide.IARC Cancer Base No. 10. http://globocan.iarc.fr, accessed November 23, 2011
  2. Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037–45.
  3. Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: A review. Rev Recent Clin Trials 2009; 4: 56–62.
  4. Poston G.J, Figueras J, Giuliante F et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26: 4828–33.
  5. Aloia T.A, Adam R, Azoulay D et al. Outcome following hepatic resection of metastatic renal tumors: The Paul Brousse Hospital experience. HPB (Oxford) 2006; 8: 100–5.
  6. Okines A, Puerto O.D, Cunningham D et al. Surgery with curative - intent in patients treated with firstline chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033–8.
  7. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830–5.
  8. Wong R, Cunningham D, Barbachano Y et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor - risk colorectal liver - only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042–8.
  9. Masi G, Loupakis F, Salvatore L et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first - line treatment for metastatic colorectal cancer: A phase 2 trial. Lancet Oncol 2010; 11: 845–52.
  10. Kishi Y, Zorzi D, Contreras C.M et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010; 17: 2870–6.
  11. Li D.B, Ye F, Wu X.R et al. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol 2013; 19 (5): 761–8.
  12. Wicherts D.A, de Haas R.J, Sebagh M et al. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 2011; 98: 399–407.
  13. Reddy S.K, Morse M.A, Hurwitz H.I et al. Addition of bevacizumab to irinotecan - and oxaliplatin - based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206 (1): 96–106.
  14. Mahfud M, Breitenstein S, El-Badry A.M et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case - matched control study. World J Surg 2010: 34 (1): 92–100.
  15. Figueras J, Lopez-Ben S, Alsina M et al. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. Clin Transl Oncol 2013; 15 (6): 460–6.
  16. Bruera G, Cannita K, Di Giacomo D et al. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Med 2012; 8 (10): 135.
  17. Stremitzer S, Stift J, Gruenberger B et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 2012; 99 (11): 1575–82.
  18. Беляева А.В., Моисеенко А.Б., Гуляев А.В. Современные представления о прогностических факторах колоректального рака. Вопр. онкологии. 2011; 57(3): 279–85.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).